Ahead of the ePRO Curve?
On
Paula Brown Stafford, executive vice president, Integrated Clinical Services for Quintiles told Applied Clinical Trials that it has completed nearly 700 trials using EDC to date. And of the active trials it manages, 75% of the data is collected electronically. “It is a standard now and paper is the exception to the rule,” said Stafford.
Outside of ePRO, which encompasses invivodata’s product lines that support the electronic delivery of the Patient Reported Outcomes instrument, invivodata also brings its substantive PRO Consulting services to the table in this partnership. Doug Engfer, co-founder and CEO of invivodata elaborated and said, “The consulting side will work with Quintiles health economics and outcomes research to fit the PRO data collection within the go to market models of the sponsor and make sure that endpoints meet the market strategy of the drug.”
Stafford noted that she has seen only a slight increase in sponsors requesting PRO or ePRO in recent years. However, she said, “We think they should be collecting more data and designing more trials with PRO data. And we do see from the December release of the Final Guidance that FDA is urging more use of PRO and data from the patient perspective.” And Stafford’s plans are to be there with the tools when her clients request them, because she does believe the use of PRO and ePRO will increase.
Choosing a preferred provider in ePRO was an extension to its choice of Phase Forward for the same status as EDC provider in 2006. “While we will use whichever provider the sponsor wants to, but if we have the choice we will use the preferred provider,” explained Stafford. “We see efficiencies in using the product numerous times, in terms of working with the product as well as a better relationship with the provider.”
In choosing to bestow preferred provider status, Quintiles has to have some experience working with the company. In invivodata’s case, approximately a six-year history, with over 20 joint studies, involving over 10,000 patients. Stafford said, “With invivodata, we saw the best fit with their technology and with their representatives.”
In addition to Phase Forward and invivodata, other preferred providers for
Meanwhile, with FDA’s support on the side of the patient perspective in the Final Guidance and Quintiles' choice of invivodata as its ePRO Partner, invivodata is feeling both humbled and vindicated. “This partnership with Quintiles as the leading pharmaceutical services company reinforces that we are the leader in ePRO,” said Engfer. “And it validates our approach to collecting PRO data.”
The company founders—Saul Shiffman, PhD, Jean Paty, PhD and Doug Engfer—joined to form
Related Blog,
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025